Genen­tech adds a new pro­gram for Syn­dax’s lead can­cer drug to its Tecen­triq com­bo plat­form

Genen­tech is adding a new tri­al us­ing Syn­dax’s lead drug enti­no­s­tat to its plat­form for test­ing new drug com­bi­na­tions with its PD-L1 drug Tecen­triq (ate­zolizum­ab).

The can­cer drug gi­ant set up a pro­gram called Mor­pheus for these com­bos. Now their re­searchers will use the com­bi­na­tion ther­a­py to treat metasta­t­ic HR+, HER2- breast can­cer.

This is the sec­ond de­vel­op­ment deal that Syn­dax $SNDX has put to­geth­er with Genen­tech. The first cen­tered on a com­bi­na­tion of the biotech’s lead ef­fort with Tecen­triq in a Phase Ib/II tri­al for triple neg­a­tive breast can­cer. The Phase II part of that study is ex­pect­ed to com­plete en­roll­ment in the first half of this year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER